Payment for in-silico modelling of checkpoint inhibitor

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is now entitled to a payment from Sareum Holdings plc (“Sareum”) for a three month modelling project conducted by the Company in 2010 in support of Sareum’s cancer drug joint research program with The Institute of Cancer Research (ICR) and Cancer Research Technology Limited (CRT), as originally announced by RNS on 16th March 2010. The program was licensed to the CRT Pioneer Fund in September 2013 and a co-investment partnership with Sareum was formed to progress the candidate drug through clinical trials.

Please click here for more information.